Ariceum Therapeutics Launches with EUR 25M Series A to Advance Lead Asset, Satoreotide, for the Treatment of Low- and High-Grade Neuroendocrine Cancers.
Optimum Strategic Communications is pleased to support the recent launch of Ariceum Therapeutics, a private biotechnology company developing a radiopharmaceutical product for the diagnosis and systemic targeted radiation therapy of certain hard-to-treat cancers, with an oversubscribed EUR 25 million Series A Financing round.
Ariceum’s lead asset and proprietary peptide derivative, satoreotide is a radiopharmaceutical drug and an antagonist of the somatostatin type 2 (SST2) receptor which is overexpressed in many cancers, including certain hard-to-treat cancers such as small cell lung cancer (SCLC), high-grade neuroendocrine tumours (NETs) and neuroblastoma, an aggressive, rare type of cancer that occurs mainly in young children. Satoreotide is in early clinical development and, to date, has been administered to more than 100 patients including more than 150 therapeutic administrations.
Ariceum was co-founded by EQT Life Sciences (formerly LSP) and HealthCap who also co-led the financing that was joined by Pureos Bioventures.
Manfred Rüdiger, PhD, Chief Executive Officer of Ariceum Therapeutics spoke with Tyler Patchen of Endpoints News to discuss the exciting launch, highlighting what sets Ariceum Therapeutics apart from other companies within the radiopharmaceutical arena and the pathway forward for Ariceum Therapeutics.
Read full article here.